Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Monsanto shareholders...

    Monsanto shareholders approve merger with Bayer

    Written by savita thakur thakur Published On 2016-12-15T11:32:26+05:30  |  Updated On 15 Dec 2016 11:32 AM IST
    Monsanto shareholders approve merger with Bayer

    New Delhi: Shareholders of US biotechnology major Monsanto have approved its close to USD 66 billion merger deal with German pharma and chemical firm Bayer AG.


    A decision in this regard was taken at a special meeting of shareholders held.


    Nearly 99 per cent of all votes cast by Monsanto shareholders were in favour of the merger, its Indian subsidiary Monsanto India said in a BSE filing. "Under the terms of the merger agreement, Monsanto share owners will get USD 128 per share in cash at the closing of the merger," it said. The merger is subject to regulatory approvals.


    The deal is expected to be closed at the end of 2017. The merger deal was announced back in May, but it went through after Bayer made a third sweetened offer of USD 128 per share, marking the largest all-cash deal on record.

    The Monsanto shareholders also approved "the proposal to approve on an advisory (non-binding) basis, certain compensation that may be paid or become payable to the company's named executive officers in connection with the merger". "We are pleased we received such a strong support from our share owners. This is an important milestone as we work to combine out two complementary companies and deliver on our shared vision for the future of agriculture," Monsanto Chairman and CEO Hugh Grant said.

    Bayer AG CEO Werner Baumann said, "The acquisition of Monsanto is driven by strong belief that this combination can help address the growing challenges facing farmers and the overall agriculture today and in future." He added: "Together, Bayer and Monsanto will be able to offer the new, innovative solutions that our customers need. We look forward to completing the transaction and working closely with Monsanto to ensure a successful integration."


    Monsanto has a significant presence in India and has played a key role in increasing cotton output through its genetically-modified (GM) technologies.

    BayerBayer AGmergerMonsanto shareholderspharma newspharma news india
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok